Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

European Neuropsychopharmacology

Volumn 25, Issue 5, 2015, Pages 713-724

  Bayer, Thomas A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Amyloid; Clinical trial; Immunization; Proteinopathy

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; PROTEIN AGGREGATE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; CONFORMATIONAL TRANSITION; CORTICOBASAL DEGENERATION; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG INDUSTRY; HUMAN; IMMUNIZATION; NERVE DEGENERATION; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEFECT; REVIEW; SHY DRAGER SYNDROME; TAUOPATHY; TDP 43 PROTEINOPATHY; ANIMAL; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PROTEOSTASIS DEFICIENCIES;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEOSTASIS DEFICIENCIES;

EID: 84928268122     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.03.007     Document Type: Review

References (116)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych. Gerichtl. Med. 1907, 64:146-148.
2. Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006, 351:602-611.
3. Arendt T., Stieler J., Strijkstra A.M., Hut R.A., Rudiger J., Van der Zee E.A., Harkany T., Holzer M., Hartig W. Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 2003, 23:6972-6981.
4. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
5. Ballatore C., Lee V.M.Y., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
6. Barrow C.J., Zagorski M.G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science 1991, 253:179-182.
7. Bayer T.A., Wirths O. Intracellular accumulation of amyloid-beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front. Aging Neurosci. 2010, 10:2-8.
8. Benilova I., Karran E., De Strooper B. The toxic A[beta] oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 29:349-357.
9. Bertram L., Tanzi R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Invest. 2005, 115:1449-1457.
10. Beyer K., Ariza A. Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 2012, 1-16.
11. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
12. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol. 2010, 120:369-384.
13. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a New tangle mouse model. J. Neurosci. 2010, 30:16559-16566.
14. Braak H., Alafuzoff I., Arzberger T., Kretzschmar H., Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, 112:389-404.
15. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
16. Breyhan H., Wirths O., Duan K., Marcello A., Rettig J., Bayer T.A. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol. 2009, 117:677-685.
17. Brion J.P., Hanger D.P., Bruce M.T., Couck A.M., Flament-Durand J., Anderton B.H. Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem. J. 1991, 273:127-133.
18. Brundin P., Melki R., Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11:301-307.
19. Cairns N.J., Neumann M., Bigio E.H., Holm I.E., Troost D., Hatanpaa K.J., Foong C., White C.L., Schneider J.A., Kretzschmar H.A., Carter D., Taylor-Reinwald L., Paulsmeyer K., Strider J., Gitcho M., Goate A.M., Morris J.C., Mishra M., Kwong L.K., Stieber A., Xu Y., Forman M.S., Trojanowski J.Q., Lee V.M., Mackenzie I.R. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 2007, 171:227-240.
20. Carrell R.W., Lomas D.A. Conformational disease. Lancet 1997, 350:134-138.
21. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
22. Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckner N., Hanmer J., Davies P., O'Neill M.J., Hutton M.L., Citron M. Passive immunization with anti-tau antibodies in two transgenic models. J. Biol. Chem. 2011, 286:34457-34467.
23. Chen F., David D., Ferrari A., Gotz J. Posttranslational modifications of tau-role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 2004, 5:503-515.
24. Christensen D.Z., Bayer T.A., Wirths O. Intracellular A[beta] triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol. Aging 2010, 31:1153-1163.
25. Christensen D.Z., Kraus S.L., Flohr A., Cotel M.C., Wirths O., Bayer T.A. Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol. 2008, 116:647-655.
26. Christensen D.Z., Schneider-Axmann T., Lucassen P.J., Bayer T.A., Wirths O. Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol. 2010, 119:555-566.
27. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21:249-254.
28. Colby D.W., Prusiner S.B. De novo generation of prion strains. Nat. Rev. Microbiol. 2011, 9:771-777.
29. Cremades N., Cohen S.I., Deas E., Abramov A.Y., Chen A.Y., Orte A., Sandal M., Clarke R.W., Dunne P., Aprile F.A., Bertoncini C.W., Wood N.W., Knowles T.P., Dobson C.M., Klenerman D. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 2012, 149:1048-1059.
30. DeKosky S.T., Ikonomovic M.D., Gandy S. Traumatic Brain Injury - Football, Warfare, and Long-Term Effects. N. Engl. J. Med. 2010, 363:1293-1296.
31. Delrieu J., Ousset P.J., Caillaud C., Vellas B. Clinical trials in Alzheimer's disease': immunotherapy approaches. J. Neurochem. 2012, 120:186-193.
32. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98:8850-8855.
33. Dickson D.W. Neuropathology of non-Alzheimer degenerative disorders. Int. J. Clin. Exp. Pathol. 2009, 3:1-23.
34. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
35. Dong J., Atwood C.S., Anderson V.E., Siedlak S.L., Smith M.A., Perry G., Carey P.R. Metal binding and oxidation of amyloid-β within isolated senile plaque cores: raman microscopic evidence. Biochemistry 2003, 42:2768-2773.
36. Drechsel D.N., Hyman A.A., Cobb M.H., Kirschner M.W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 1992, 3:1141-1154.
37. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118:5-36.
38. Ghiso J., Rostagno A., Tomidokoro Y., Lashley T., Bojsen-Moller M., Braendgaard H., Plant G., Holton J., Lal R., Revesz T., Frangione B. Genetic alterations of the BRI2 gene: familial British and Danish dementias. Brain Pathol. 2006, 16:71-79.
39. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
40. Glenner G.G., Wong C.W. AlzheimerDs disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
41. Goedert M., Clavaguera F., Tolnay M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010, 33:317-325.
42. Gong C.X., Liu F., Grundke-Iqbal I., Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transm. 2005, 112:813-838.
43. Gouras G.K., Tampellini D., Takahashi R.H., Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010, 119:523-541.
44. Gustke N., Trinczek B., Biernat J., Mandelkow E.M., Mandelkow E. Domains of tau protein and interactions with microtubules. Biochemistry 1994, 33:9511-9522.
45. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
46. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
47. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
48. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A.R. Long-term effects of Aβ42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
49. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Heutink P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
50. Iwai A., Masliah E., Sundsmo M.P., DeTeresa R., Mallory M., Salmon D.P., Saitoh T. The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Brain Res 1996, 720:230-234.
51. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
52. Jawhar S., Wirths O., Bayer T.A. Pyroglutamate Abeta-a hatchet man in Alzheimer disease. J. Biol. Chem. 2011, 286:38825-38832.
53. Joutel A., Corpechot C., Ducros A., Vahedi K., Chabriat H., Mouton P., Alamowitch S., Domenga V., Cecillion M., Marechal E., Maciazek J., Vayssiere C., Cruaud C., Cabanis E.-A., Ruchoux M.M., Weissenbach J., Bach J.F., Bousser M.G., Tournier-Lasserve E. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383:707-710.
54. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Mueller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
55. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum. Vaccines 2010, 6:931-935.
56. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
57. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
58. Kumar S., Rezaei-Ghaleh N., Terwel D., Thal D.R., Richard M., Hoch M., Mc Donald J.M., Wullner U., Glebov K., Heneka M.T., Walsh D.M., Zweckstetter M., Walter J. Extracellular phosphorylation of the amyloid [beta]-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J. 2011, 30:2255-2265.
59. Kuo Y.M., Webster S., Emmerling M.R., De Lima N., Roher A.E. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta 1998, 1406:291-298.
60. Kwong L.K., Neumann M., Sampathu D.M., Lee V.M., Trojanowski J.Q. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007, 114:63-70.
61. Lee V.M., Brunden K.R., Hutton M., Trojanowski J.Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harbor Perspect. Med. 2011, 1:a006437.
62. Li J.-Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Bjorklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
63. Mackenzie I.R., Bigio E.H., Ince P.G., Geser F., Neumann M., Cairns N.J., Kwong L.K., Forman M.S., Ravits J., Stewart H., Eisen A., McClusky L., Kretzschmar H.A., Monoranu C.M., Highley J.R., Kirby J., Siddique T., Shaw P.J., Lee V.M., Trojanowski J.Q. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007, 61:427-434.
64. Martin L., Latypova X., Terro F. Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochem. Int. 2011, 58:458-471.
65. Masliah E., Iwai A., Mallory M., Ueda K., Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 1996, 148:201-210.
66. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., Games D., Schenk D. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
67. Masliah E., Rockenstein E., Mante M., Crews L., Spencer B., Adame A., Patrick C., Trejo M., Ubhi K., Rohn T.T., Mueller-Steiner S., Seubert P., Barbour R., McConlogue L., Buttini M., Games D., Schenk D. Passive Immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease. PLoS ONE 2011, 6:e19338.
68. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. 1985, 82:4245-4249.
69. Masuda M., Hasegawa M., Nonaka T., Oikawa T., Yonetani M., Yamaguchi Y., Kato K., Hisanaga S., Goedert M. Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett. 2009, 583:787-791.
70. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., Janus C., Chishti M.A., Horne P., Westaway D., Fraser P.E., Mount H.T., Przybylski M., St George-Hyslop P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
71. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
72. Meyer-Luehmann M., Stalder M., Herzig M.C., Kaeser S.A., Kohler E., Pfeifer M., Boncristiano S., Mathews P.M., Mercken M., Abramowski D., Staufenbiel M., Jucker M. Extracellular amyloid formation and associated pathology in neural grafts. Nat. Neurosci. 2003, 6:370-377.
73. Milton N.G.N. Phosphorylation of amyloid-[beta] at the serine 26 residue by human cdc2 kinase. NeuroReport 2001, 12:3839-3844.
74. Morgan D. Immunotherapy for Alzheimer's disease. J. Int. Med. 2011, 269:54-63.
75. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
76. Mori H., Ishii K., Tomiyama T., Furiya Y., Sahara N., Asano S., Endo N., Shirasawa T., Takio K. Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. Tohoku J. Exp. Med. 1994, 174:251-262.
77. Mullard A. 2010 FDA drug approvals. Nat. Rev. Drug. Discovery 2011, 10:82-85.
78. Neumann M., Kwong L.K., Truax A.C., Vanmassenhove B., Kretzschmar H.A., Van Deerlin V.M., Clark C.M., Grossman M., Miller B.L., Trojanowski J.Q., Lee V.M. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J. Neuropathol. Exp. Neurol. 2007, 66:177-183.
79. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
80. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
81. Oueslati A., Fournier M., Lashuel H.A. Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Progress in Brain Research 2010, 115-145. Elsevier, (Chapter 7). B. Anders, M.A. Cenci (Eds.).
82. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug. Discovery 2010, 9:203-214.
83. Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995, 270:23895-23898.
84. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., Niinistö L., Halonen P., Kontula K. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N. Engl. J. Med. 1995, 333:1242-1248.
85. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
86. Portelius E., Bogdanovic N., Gustavsson M.K., Volkmann I., Brinkmalm G., Zetterberg H., Winblad B., Blennow K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010, 120:185-193.
87. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., Black R.S. Progress in the active immunotherapeutic approach to alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodeg. Dis. 2008, 5:194-196.
88. Prusiner S.B. Molecular biology of prion disease. Science 1991, 252:1515-1522.
89. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature 1988, 332:323-327.
90. Roher A., Lowenson J., Clarke S., Wolkow C., Wang R., Cotter R., Reardon I., Zurcher-Neely H., Heinrikson R., Ball M. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 1993, 268:3072-3083.
91. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
92. Samadi H., Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin. Biol. Ther. 2011, 11:787-798.
93. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
94. Schenk D.B., Seubert P., Grundman M., Black R. Aβ Immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodeg. Dis 2005, 2:255-260.
95. Schlenzig D., Manhart S., Cinar Y., Kleinschmidt M., Hause G., Willbold D., Funke S.A., Schilling S., Demuth H.-U. Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. Biochemistry 2009, 48:7072-7078.
96. Schlenzig D., Rönicke R., Cynis H., Ludwig H.-H., Scheel E., Reymann K., Saido T., Hause G., Schilling S., Demuth H.-U. N-terminal Pyroglutamate (pGlu) formation of Aβ38 and Aβ40 Enforces Oligomer Formation and Potency to Disrupt Hippocampal LTP. J. Neurochem. 2012, 121:774-784.
97. Selkoe D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 2011, 17:1060-1065.
98. Shimizu T., Matsuoka Y., Shirasawa T. Biological significance of isoaspartate and its repair system. Biol. Pharm. Bull. 2005, 28:1590-1596.
99. Sipe J.D., Cohen A.S. Review: history of the amyloid fibril. J. Struct. Biol. 2000, 130:88-98.
100. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
101. Takahashi K., Adachi K., Yoshizaki K., Kunimoto S., Kalaria R.N., Watanabe A. Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum, leading to impaired cell proliferation. Hum. Mol. Genet. 2010, 19:79-89.
102. Tanzi R.E., Gusella J.F., Watkins P.C., Bruns G.A.P., George-Hyslop P.H., Van Keuren M.L., Patterson D., Pagan S., Kurnit D.M., Neve R.L. The amyloid protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235:880-884.
103. Tomiyama T., Asano S., Furiya Y., Shirasawa T., Endo N., Mori H. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues. J. Biol. Chem. 1994, 269:10205-10208.
104. Tournier-Lasserve E., Iba-Zizen M., Romero N., Bousser M. Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy. Stroke 1991, 22:1297-1302.
105. Uenaka K., Nakano M., Willis B.A., Friedrich S., Ferguson-Sells L., Dean R.A., Ieiri I., Siemers E.R. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and White Patients with mild to moderate alzheimer disease. Clin. Neuropharm. 2012, 35:25-29.
106. Urushitani M., Ezzi S.A., Julien J.P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2007, 104:2495-2500.
107. Viitanen M., Kalimo H. CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia. Ann. NY Acad. Sci. 2000, 903:273-284.
108. Viscomi M., D'Amelio M. The "Janus-Faced Role" of autophagy in neuronal sickness: focus on neurodegeneration. Mol. Neurobiol. 2012, 46:513-521.
109. Walker L.C., LeVine Iii H. The cerebral proteopathies. Neurobiol. Aging 2000, 21:559-561.
110. Wang I.F., Wu L.-S., Shen C.K.J. TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol. Med. 2008, 14:479-485.
111. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-αβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745-3751.
112. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., Maguire R.P., Blennow K., Lundmark J., Staufenbiel M., Orgogozo J.-M., Graf A. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012, 11:597-604.
113. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.U., Bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118:487-496.
114. Wirths O., Erck C., Martens H., Harmeier A., Geumann C., Jawhar S., Kumar S., Multhaup G., Walter J., Ingelsson M., Degerman-Gunnarsson M., Kalimo H., Huitinga I., Lannfelt L., Bayer T.A. Identification of low molecular weight pyroglutamate Abeta oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 2010, 285:41517-41524.
115. Wirths O., Multhaup G., Bayer T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem. 2004, 91:513-520.
116. Wittnam J.L., Portelius E., Zetterberg H., Gustavsson M.K., Schilling S., Koch B., Demuth H.-U., Blennow K., Wirths O., Bayer T.A. Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J. Biol. Chem. 2012, 287:8154-8162.